{ "market" : {"NAME" : "U.S.", "ID" : "us_market", "TZ" : "ET", "TZOFFSET" : "-18000", "open" : "1257863431", "close" : "1257886831", "flags" : {}} , "STREAMER_SERVER" : "http://streamerapi.finance.yahoo.com","arrowAsChangeSign" : false,"throttleInterval": "1000"}
globenewswire

Athersys to Present At Lambert-Edwards SMID-West Stock Conference

  • Press Release
  • Source: Athersys, Inc.
  • On 8:30 am EST, Monday December 8, 2008

CLEVELAND, Dec. 8, 2008 (GLOBE NEWSWIRE) -- Athersys, Inc. (NasdaqCM:ATHX - News) today announced that William (B.J.) Lehmann, President and Chief Operating Officer, will present to investors and analysts at the Lambert-Edwards SMID-West Stock Conference, to be held December 11, 2009, at the Palmer House Hilton Hotel in Chicago, Illinois.

Related Quotes

SymbolPriceChange
ATHX1.000.00
Chart for Athersys, Inc.
{"s" : "athx","k" : "c10,l10,p20,t10","o" : "","j" : ""}

SMID-West 2008 is an invitation-only event to introduce buy-side and sell-side analysts to the management teams of top-performing small-and mid-cap (SMID) companies. The one-on-one and small-group meeting format is open to professional investors. A webcast replay of the company's presentation will be available via the company's web site at: http://www.athersys.com, under the Investors section, following the conference.

Lambert, Edwards & Associates, one of the Midwest's top investor relations firms, is hosting SMID-West 2008 in partnership with PR Newswire, Thomson and Roadcast(tm).

About Athersys, Inc.

Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company is developing MultiStem(r), a patented, adult-derived ``off-the-shelf'' stem cell product platform for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications. The company is also developing a portfolio of other therapeutic programs, including orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE). More information is available at http://www.athersys.com.

The Athersys, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4548

Contact:

          Athersys, Inc.
William (B.J.) Lehmann, J.D.,
President and Chief Operating Officer
(216) 431-9900
bjlehmann@athersys.com

In-Site Communications
Lisa M. Wilson
(917) 543-9932
lwilson@insitecony.com

Sponsored Links

Copyright © 2009 GlobeNewswire. All rights reserved. Redistribution of this content is expressly prohibited without prior written consent. GlobeNewswire makes no claims concerning the accuracy or validity of the information, and shall not be held liable for any errors, delays, omissions or use thereof.